These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 1503912)

  • 1. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
    Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
    Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis.
    Cummings TJ; Provenzale JM; Hunter SB; Friedman AH; Klintworth GK; Bigner SH; McLendon RE
    Acta Neuropathol; 2000 May; 99(5):563-70. PubMed ID: 10805102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
    Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
    J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein and epidermal growth factor receptor expression in human astrocytomas.
    Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP
    J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
    Lipponen P; Eskelinen M
    Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas.
    Bouvier-Labit C; Chinot O; Ochi C; Gambarelli D; Dufour H; Figarella-Branger D
    Neuropathol Appl Neurobiol; 1998 Oct; 24(5):381-8. PubMed ID: 9821169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival.
    Hara A; Saegusa M; Mikami T; Okayasu I
    J Clin Pathol; 2001 Nov; 54(11):860-5. PubMed ID: 11684721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.
    Ranuncolo SM; Varela M; Morandi A; Lastiri J; Christiansen S; Bal de Kier Joffé E; Pallotta MG; Puricelli L
    J Neurooncol; 2004 Jun; 68(2):113-21. PubMed ID: 15218947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining.
    Hwang SL; Hong YR; Chai CY; Lin HJ; Howng SL
    Kaohsiung J Med Sci; 1998 Oct; 14(10):607-15. PubMed ID: 9819502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleolar organizer region score and Ki-67 labelling index in high-grade gliomas and metastatic brain tumours.
    Hara A; Hirayama H; Sakai N; Yamada H; Tanaka T; Mori H
    Acta Neurochir (Wien); 1991; 109(1-2):37-41. PubMed ID: 1648862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas.
    Thotakura M; Tirumalasetti N; Krishna R
    J Cancer Res Ther; 2014; 10(3):641-5. PubMed ID: 25313753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
    Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
    APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
    Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
    Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
    Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
    Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical value of Ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas.
    Tihan T; Davis R; Elowitz E; DiCostanzo D; Moll U
    Arch Pathol Lab Med; 2000 Jan; 124(1):108-13. PubMed ID: 10629140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
    Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
    Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular markers relating to malignant progression in Grade II astrocytoma.
    Yue WY; Yu SH; Zhao SG; Chen ZP
    J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.